Literature DB >> 32936695

Response to coronavirus 2019 in Veterans Health Administration facilities participating in an implementation initiative to enhance access to medication for opioid use disorder.

Allison M Gustavson1, Adam J Gordon2,3, Marie E Kenny1, Haley McHenry4, Julie Gronek5, Princess E Ackland1,6, Hildi J Hagedorn1,7.   

Abstract

The actions needed to mitigate the spread of the coronavirus 2019 (COVID-19) have forged rapid paradigm shifts across healthcare delivery. In a time of crisis, continued access to and delivery of medication for opioid use disorder (M-OUD) is essential to save lives. However, prior to COVID-19, large variability in M-OUD adoption existed across the Veteran Health Administration (VHA) and it is unknown whether the COVID-19 pandemic exacerbated this divide. For the past two years, our team worked with eight VHA facilities to enhance adoption of M-OUD through a multi-component implementation intervention. This commentary explores these providers' responses to COVID-19 and the subsequent impact on their progress toward increasing adoption of M-OUD. Briefly, the loosening of regulatory restrictions fostered accelerated adoption of M-OUD, rapid support for telehealth offered a mechanism to increase M-OUD access, and reevaluation of current practices surrounding M-OUD strengthened adoption. Overall, during the COVID-19 crisis, facilities and providers responded positively to the call for increased access to M-OUD and appropriate care of patients with OUD. The VHA providers' responses and continued progress in enhancing M-OUD amidst a crisis may, in part, be attributable to their participation in an implementation effort prior to COVID-19 that established resources, expert support, and a community of practice. We anticipate the themes presented are generalizable to other healthcare systems grappling to deliver care to patients with OUD during a crisis. We propose areas of future research and quality improvement to continue to provide access and high quality, life-saving care to patients with OUD.

Entities:  

Keywords:  COVID-19; coronavirus; implementation; medication for opioid use disorder; opioid use disorder

Mesh:

Substances:

Year:  2020        PMID: 32936695      PMCID: PMC8667808          DOI: 10.1080/08897077.2020.1809609

Source DB:  PubMed          Journal:  Subst Abus        ISSN: 0889-7077            Impact factor:   3.716


  34 in total

1.  Implementing shared decision making in routine mental health care.

Authors:  Mike Slade
Journal:  World Psychiatry       Date:  2017-06       Impact factor: 49.548

2.  Psychiatric comorbidity, red flag behaviors, and associated outcomes among office-based buprenorphine patients following Hurricane Sandy.

Authors:  Arthur R Williams; Babak Tofighi; John Rotrosen; Joshua D Lee; Ellie Grossman
Journal:  J Urban Health       Date:  2014-04       Impact factor: 3.671

3.  Will There Be an Epidemic of Corollary Illnesses Linked to a COVID-19-Related Recession?

Authors:  M Harvey Brenner
Journal:  Am J Public Health       Date:  2020-05-14       Impact factor: 9.308

4.  Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.

Authors:  Adam J Gordon; Karen Drexler; Eric J Hawkins; Jennifer Burden; Nodira K Codell; Amy Mhatre-Owens; Matthew T Dungan; Hildi Hagedorn
Journal:  Subst Abus       Date:  2020       Impact factor: 3.716

5.  Opioid use disorder patients' perceptions of healthcare delivery platforms.

Authors:  Uros Rakita; Peter Giacobbe; Chris Cavacuiti
Journal:  SAGE Open Med       Date:  2016-09-23

6.  Pain Management Best Practices from Multispecialty Organizations During the COVID-19 Pandemic and Public Health Crises-Evaluating the Risk of Infection Associated with Corticosteroid Injections.

Authors:  Jatinder S Gill; Janis L Breeze; Thomas T Simopoulos
Journal:  Pain Med       Date:  2020-08-01       Impact factor: 3.750

Review 7.  The Use of Non-invasive Vagus Nerve Stimulation to Treat Respiratory Symptoms Associated With COVID-19: A Theoretical Hypothesis and Early Clinical Experience.

Authors:  Peter Staats; Georgios Giannakopoulos; Justyna Blake; Eric Liebler; Robert M Levy
Journal:  Neuromodulation       Date:  2020-05-12

8.  Editorial: Challenges to Opioid Use Disorders During COVID-19.

Authors:  Yankun Sun; Yanping Bao; Thomas Kosten; John Strang; Jie Shi; Lin Lu
Journal:  Am J Addict       Date:  2020-04-13

9.  Modeling COVID-19 and Its Impacts on U.S. Immigration and Customs Enforcement (ICE) Detention Facilities, 2020.

Authors:  Michael Irvine; Daniel Coombs; Julianne Skarha; Brandon Del Pozo; Josiah Rich; Faye Taxman; Traci C Green
Journal:  J Urban Health       Date:  2020-08       Impact factor: 3.671

10.  The COVID-19 Pandemic and Rapid Implementation of Adolescent and Young Adult Telemedicine: Challenges and Opportunities for Innovation.

Authors:  Angela Barney; Sara Buckelew; Veronika Mesheriakova; Marissa Raymond-Flesch
Journal:  J Adolesc Health       Date:  2020-05-14       Impact factor: 5.012

View more
  1 in total

1.  Research priorities for expanding access to methadone treatment for opioid use disorder in the United States: A National Institute on Drug Abuse Center for Clinical Trials Network Task Force report.

Authors:  Paul J Joudrey; Gavin Bart; Robert K Brooner; Lawrence Brown; Julie Dickson-Gomez; Adam Gordon; Sarah S Kawasaki; Jane M Liebschutz; Edward Nunes; Dennis McCarty; Robert P Schwartz; José Szapocnik; Madhukar Trivedi; Judith I Tsui; Arthur Williams; Li-Tzy Wu; David A Fiellin
Journal:  Subst Abus       Date:  2021       Impact factor: 3.716

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.